New offerings combine a variety of Medidata technologies and learnings from thousands of previous trials to streamline study management for Phase II and Phase III studies in specified therapeutic areas, reinforcing FDA guidance for patient-centered study design and execution Collaboration advances shared objectives for investment in the Kingdom of Saudi Arabia and the rest of the region with EIG’s targeted US$1 billion dedicated regional fundMedidata Launches Bundled Solutions to Support Oncology and Vaccine Trials, Accelerating Study Design and Execution
Hassana Investment Company and EIG Sign MoU for Strategic Collaboration on Middle East Infrastructure
| ABX | ||
| 966.134 | ||
| -6.3480 | -0.0065% | |
| BISNIS-27 | ||
| 520.192 | ||
| 9.7170 | 0.0190% | |
| DBX | ||
| 1,960.081 | ||
| 18.9240 | 0.0097% | |
| ECONOMIC30 | ||
| 118.609 | ||
| 1.8760 | 0.0161% | |
| ESGQKEHATI | ||
| 125.244 | ||
| 2.1370 | 0.0174% | |
| ESGSKEHATI | ||
| 124.778 | ||
| 2.0590 | 0.0168% | |
| I-GRADE | ||
| 206.206 | ||
| 4.3670 | 0.0216% | |
| AUDRP | ||
| 10,104.600 | ||
| -12.5000 | -0.1236% | |
| EURRP | ||
| 16,840.200 | ||
| -40.2000 | -0.2381% | |
| JPYRP | ||
| 103.178 | ||
| -0.2920 | -0.2822% | |
| SINRP | ||
| 11,920.400 | ||
| -37.6000 | -0.3144% | |
| USDRP | ||
| 16,170.000 | ||
| -20.0000 | -0.1235% | |
